Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: General and other
Stage/Subtype:  mixed glioma, adult
Trial Type:  Treatment
Results 1-25 of 41 for your search:
Start Over
Light Sedation or Intubated General Anesthesia in Reducing Complications and Length of Hospital Stay in Patients With Brain Cancer Undergoing Craniotomy
Status: Active
Phase: Phase IV
Type: Supportive care, Treatment
Age: 19 and over
Trial IDs: OSU-12161, NCI-2014-01110, 2014C0007, NCT02193568
Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
Carboplatin with or without Vincristine Sulfate in Treating Younger Patients with Previously Untreated Low Grade Glioma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and younger
Trial IDs: LCH 14C03, NCI-2015-01146, 2014-15932, LGG-14C03, NCT02455245
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00002868, NCI-2013-00786, 2868, CR00002456, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Plerixafor after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: BRN0023, NCI-2013-02012, 5136, NCT01977677
MK-3475 in Combination with MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201501072, NCI-2015-00119, 14-x326, NCT02311582
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BMX-HGG-001, NCI-2016-00288, NCT02655601
Combination Chemotherapy with or without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients with Malignant Brain Tumors
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: IRB00000922, NCI-2013-00781, CR00018679, CR00021317, CR00022743, CR00023930, eIRB #922, MR00041590, ONC-02019-L, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Aminolevulinic Acid in Measuring Brain Tumors in Patients With High Grade Glioma Undergoing Surgery
Status: Active
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 to 72
Trial IDs: 10101, NCI-2011-01264, NCT01116661
Nilotinib in Treating Patients with Recurrent Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 091728, NCI-2010-01839, NCI-2012-02871, NCT01140568
Proton Beam Radiation Therapy in Treating Patients with Low Grade Gliomas and Favorable Grade 3 Gliomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-439, NCI-2011-00915, NCT01358058
Everolimus With or Without Temozolomide in Treating Patients With Newly-Diagnosed Low-Grade Gliomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 131012, NCI-2014-00749, 081184, CRAD001CUS225T, NCT02023905
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 08109, NCI-2011-01701, NCT00823459
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients with Recurrent Malignant Glioma
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 15C03, NCI-2016-00665, STU00202283, NCT02794883
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Recurrent or Refractory Tumors in the Brain and/or Spinal Cord
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: 03-133, NCI-2016-00928, MSKCC-03133, NCT00089245
Pegylated Liposomal Irinotecan in Treating Patients With Recurrent High-Grade Gliomas
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 08103, NCI-2011-01271, H5941-32646, UCSF-H5941-32646-01, UCSF-08103, H5941-32646-01, NCT00745082, NCT00734682
Plerixafor and Bevacizumab in Treating Patients with Recurrent High-Grade Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-329, NCI-2012-00149, MAMO0909-6, NCT01339039
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: ATI001-102, NCI-2014-00752, NCT02026271
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG120-C-002, NCI-2014-00868, NCT02073994
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients with Recurrent High Grade Gliomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.528, NCI-2014-01344, 2013-12, 3007, NCT02186509
Start Over